IntegenX Secures $40M in Series C Funding
IntegenX Inc., a Pleasanton, CA-based developer of rapid human DNA identification technology and DNA sequencing library preparation systems, has secured $40m in Series C funding.
The round was led by new investor Essex Woodlands, with participation from existing investors Domain Associates, QuestMark Partners, Greenspring Associates, Cross Creek Capital, RONAholdings LLC, Samsung Ventures, and strategic partner In-Q-Tel.
The company intends to use the funding to accelerate development of its product pipeline and the commercialization of its RapidHIT™ 200 Human Identification System into domestic and international markets.
The RapidHIT 200 is a sample-to-profile biometric system designed to enable law enforcement, government agencies, and forensic laboratories worldwide to accurately provide real-time human DNA analysis.
Led by CEO Stevan Jovanovich, Ph.D., IntegenX also offers:
- the Apollo 324, a system that automates next-generation sequence library preparation workflows by using bead technology to execute high-performance isolation and purification of nucleic acids (DNA, RNA, plasmid and so on) and proteins;
- GenTegra™ and GenPlate® products, which stabilize DNA, RNA, whole blood, and biological fluids, allowing dry-state room temperature storage with essentially no degradation.
In conjunction with the funding, Ronald Eastman of Essex Woodlands and Ben Shapiro of QuestMark Partners will join the company’s Board of Directors.